Movement Alert|Twist Bioscience Corp falls 6.62% in Regular Trading, target price cuts and slower AI drug discovery growth weigh

Market Focus11-16

On November 16, Twist Bioscience Corp fell 6.62% in Regular Trading, trading at $103.54/share, with turnover of $21.397 million.

The move aligns with continued market digestion of a post-earnings reset in growth expectations, alongside additional analyst target price reductions that have pressured sentiment.

Twist Bioscience Corp previously reported fiscal fourth-quarter revenue of $126.6 million and a loss of $0.32 per share, both better than consensus, while fiscal first-quarter revenue guidance of $130 million to $132 million and full-year revenue guidance of $550 million to $560 million were also slightly above expectations. Even so, investors remained focused on signals that AI drug discovery-related growth could slow in fiscal 2027. More recently, analysts lowered price targets, including UBS to $120, after earlier cuts by Jefferies to $125 and Guggenheim to $150, reinforcing pressure on the shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment